Osteonecrosis of the Jaw and Nonmalignant Disease: Is There an Association with Rheumatoid Arthritis?
Géraldine Lescaillea b c, Amélie E. Coudertd, Vanessa Baaroune f, Marie-José Javelote f, Martine Esther Cohen-Solald, Ariane Berdald, P. Goudotd, J. Azérade f, B. Ruhine f, Vianney Descroixd
- aOral Surgery Department and the Stomatology and Maxillofacial Surgery Department, and INSERM, UMR-S 606, Hôpital Lariboisière, Pitié-Salpêtrière University Hospital, Paris Diderot University, Paris, France
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
OBJECTIVE: To review cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ) occurring in association with benign disease and to describe and compare the clinical course and outcome for patients with BRONJ and rheumatoid arthritis (RA) or osteoporosis. METHODS: We retrospectively reviewed observations of all patients referred for treatment and followup for BRONJ from January 2007 to December 2011. Only patients with malignant disease were excluded. Demographic data, medical history, maxillofacial findings, BRONJ treatment, and followup were reviewed for each case. RESULTS: Over a 5-year period, we diagnosed 112 patients with BRONJ. Among these patients, 15 received bisphosphonate (BP) treatment for nonmalignant disease (mean age 65.7 ± 19.8 yrs, 80% women). Patients received BP for a variety of reasons: 8 (53%) to prevent osteoporosis in association with underlying RA; 6 (40%) to prevent idiopathic osteoporosis; and 1 (7%) to treat ankle algodystrophy. The mean oral BP exposure period was 48.4 months (median 36 mo). In 13 cases (86.6%), BRONJ was diagnosed following dental extraction. Of the 8 patients with RA, 5 (62.5%) were taking prednisone at the time of the discovery of BRONJ. Major surgery, sequestrectomy, or alveolectomy was performed in 9 patients (60%), all of whom healed within 3 to 36 months (mean 11.5 mo). Comparative analysis of all the variables showed no statistically significant differences between patients with RA and others. CONCLUSION: ONJ is a rare adverse effect of BP therapy, especially when administered orally. Within the limits of our study, we were unable to demonstrate a difference in BRONJ disease spectrum, clinical course, or outcome between patients with and those without RA.
TL;DRWithin the limits of the study, it was unable to demonstrate a difference in BRONJ disease spectrum, clinical course, or outcome between patients with and those without RA, and ONJ is a rare adverse effect of BP therapy, especially when administered orally. (Semantic Scholar)